Investigative Ophthalmology & Visual Science Cover Image for Volume 63, Issue 7
June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Use of Advanced Driver Assistance Systems by Bioptic and Normal Vision Drivers
Author Affiliations & Notes
  • Chrysanthi Stevens
    New England College of Optometry, Boston, Massachusetts, United States
  • Jing Xu
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Envision Research Institute, Wichita, Kansas, United States
  • Alex R Bowers
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Chrysanthi Stevens None; Jing Xu None; Alex Bowers None
  • Footnotes
    Support  NIH Grant T35-EY007139, Bosma Enterprises Low Vision Research Award
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2466 – F0043. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Chrysanthi Stevens, Jing Xu, Alex R Bowers; Use of Advanced Driver Assistance Systems by Bioptic and Normal Vision Drivers. Invest. Ophthalmol. Vis. Sci. 2022;63(7):2466 – F0043.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : In the majority of states, drivers with reduced visual acuity are permitted to drive with a bioptic telescope which magnifies distant objects. Advanced driver assistance systems (ADAS) have become widely available in new cars and may be helpful for drivers with impaired vision, but little is known about whether bioptic drivers use these systems. We conducted a survey to quantify usage of ADAS by bioptic compared to normal vision (NV) drivers.

Methods : The telephone survey included questions pertaining to subjects’ demographics, vision, vehicle, driving habits, experience, and use of 8 ADAS: forward collision warning, forward collision avoidance, blind spot warning, lane departure warning, rearview camera, adaptive cruise control, cruise control, and GPS navigation.

Results : 46 bioptic drivers (25 male; median age 53, range 24-84 years) and 47 NV drivers (25 male; median age 55, range 24-89) completed the survey. Weekly mileage (median 50 miles) and days per week driving (median 5) did not differ between the two groups. Yet, bioptic drivers had overall newer cars (medians 4 vs. 7 years, p =0.041) and used more ADAS (medians 3 vs. 2, p = 0.113) than NV drivers. For bioptic drivers, the most commonly used ADAS were GPS (89% bioptic, 91% NV), rearview camera (61% bioptic, 49% NV) and blind spot warning (50% bioptic, 23% NV). Forward collision warning (p=0.038), blindspot warning (p=0.009), and rearview camera (p = 0.026) were used more by bioptic than NV drivers. The ADAS most commonly believed to improve safety were blind spot warning (89% bioptic, 83% NV) and rearview camera (74% bioptic, 83% NV). The majority (83%) of bioptic drivers reported that GPS compensated for their reduced vision (compared to < 57% for other ADAS) and 50% commented that it replaced the need to read road signs. However, 37% of bioptic drivers reported difficulty using GPS because of their vision.

Conclusions : Bioptic drivers have newer cars and use ADAS more than NV drivers, most notably forward collision warning, blind spot warning, and rearview camera. For bioptic drivers, blind spot warning was reported to be most likely to improve safety and GPS was most likely to compensate for vision impairment, even though they experienced visual difficulties when using GPS and believed other ADAS to have greater potential to improve driving safety.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×